B. Riley Predicts Electromed's Q3 Earnings (NYSE:ELMD)

Electromed, Inc. (NYSE:ELMD - Free Report) - Research analysts at B. Riley issued their Q3 2025 earnings estimates for shares of Electromed in a report released on Wednesday, February 19th. B. Riley analyst K. Bauser anticipates that the company will post earnings per share of $0.19 for the quarter. B. Riley has a "Strong-Buy" rating on the stock. B. Riley also issued estimates for Electromed's Q4 2025 earnings at $0.22 EPS, FY2025 earnings at $0.80 EPS, Q1 2026 earnings at $0.20 EPS, Q2 2026 earnings at $0.22 EPS, Q3 2026 earnings at $0.26 EPS, Q4 2026 earnings at $0.31 EPS, FY2026 earnings at $1.00 EPS and FY2027 earnings at $1.16 EPS.

Separately, StockNews.com downgraded Electromed from a "strong-buy" rating to a "buy" rating in a report on Thursday.

Electromed Price Performance

NYSE:ELMD traded down $0.63 during mid-day trading on Monday, reaching $26.83. The stock had a trading volume of 93,490 shares, compared to its average volume of 111,047. Electromed has a 12 month low of $13.74 and a 12 month high of $35.56. The stock has a market capitalization of $229.58 million, a PE ratio of 35.77 and a beta of 0.33. The stock has a 50-day simple moving average of $31.36 and a two-hundred day simple moving average of $25.59.

Institutional Trading of Electromed

Several hedge funds and other institutional investors have recently made changes to their positions in the company. Jefferies Financial Group Inc. bought a new position in Electromed in the 4th quarter valued at approximately $285,000. Squarepoint Ops LLC raised its stake in shares of Electromed by 7.8% during the fourth quarter. Squarepoint Ops LLC now owns 11,366 shares of the company's stock valued at $336,000 after acquiring an additional 823 shares during the last quarter. Two Sigma Advisers LP bought a new position in shares of Electromed during the fourth quarter valued at $219,000. Two Sigma Investments LP acquired a new position in shares of Electromed during the fourth quarter worth $1,255,000. Finally, Point72 Asia Singapore Pte. Ltd. bought a new stake in shares of Electromed in the fourth quarter worth $119,000. 40.82% of the stock is currently owned by institutional investors.

Insiders Place Their Bets

In related news, Director Kathleen Skarvan sold 38,954 shares of the business's stock in a transaction on Tuesday, February 18th. The stock was sold at an average price of $29.28, for a total transaction of $1,140,573.12. Following the sale, the director now owns 32,622 shares in the company, valued at $955,172.16. The trade was a 54.42 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, Director Andrew Summers sold 50,751 shares of the company's stock in a transaction dated Monday, February 24th. The stock was sold at an average price of $27.30, for a total value of $1,385,502.30. Following the completion of the transaction, the director now directly owns 65,714 shares of the company's stock, valued at approximately $1,793,992.20. The trade was a 43.58 % decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 163,812 shares of company stock valued at $4,728,773. 14.00% of the stock is currently owned by corporate insiders.

Electromed Company Profile

Electromed, Inc develops, manufactures, markets, and sells airway clearance therapy and related products that apply high frequency chest wall oscillation (HFCWO) therapy in pulmonary care for patients of various ages in the United States and internationally. The company offers SmartVest airway clearance system for patients with compromised pulmonary functions, including bronchiectasis and cystic fibrosis, as well as neuromuscular conditions, such as cerebral palsy and amyotrophic lateral sclerosis; SmartVest SQL System; SmartVest Clearway System that consists of an inflatable therapy garment, a programmable air pulse generator, and a patented single-hose that delivers air pulses from the generator to the garment to create oscillatory pressure on the chest wall; and SmartVest Connect, a wireless technology that allows data connection between physicians and patients to track therapy performance and collaborate in treatment decisions.